Sarepta Therapeutics (NASDAQ: SRPT) insider transactions
In the twelve months to 10 November 2026, executives and directors of Sarepta Therapeutics reported 2 open-market sales of 20,426 shares ($417,410) and 0 open-market purchases, by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 4 September 2026 | Rodino-Klapac Louise | President, R&D and Tech Ops | Shares withheld for tax | −21,423 | $22.22 | 203,900 | Form 4 |
| 4 September 2026 | Rothfuss Cristin | EVP, General Counsel | Shares withheld for tax | −22,025 | $22.22 | 115,519 | Form 4 |
| 4 September 2026 | Estepan Ian Michael | Chief Operating Officer | Shares withheld for tax | −24,799 | $22.22 | 177,184 | Form 4 |
| 4 September 2026 | Wong Ryan Ho-Yan | Chief Financial Officer | Shares withheld for tax | −13,272 | $22.22 | 121,792 | Form 4 |
| 28 July 2026 | Severino Michael | Chief Executive Officer | Grant or award | +756,104 | — | 756,104 | Form 4 |
| 4 June 2026 | Barry Richard | Director | Grant or award | +16,875 | — | 2,983,542 | Form 4 |
| 4 June 2026 | Chambers Michael Andrew | Director | Grant or award | +16,875 | — | 27,535 | Form 4 |
| 4 June 2026 | Nicaise Claude | Director | Grant or award | +16,875 | — | 48,407 | Form 4 |
| 4 June 2026 | Connelly Deirdre P | Director | Grant or award | +16,875 | — | 22,100 | Form 4 |
| 4 June 2026 | Behrens M Kathleen | Director | Grant or award | +16,875 | — | 214,357 | Form 4 |
| 4 June 2026 | Wigzell Hans Lennart Rudolf | Director | Grant or award | +16,875 | — | 42,098 | Form 4 |
| 4 June 2026 | Mayo Stephen | Director | Grant or award | +16,875 | — | 18,640 | Form 4 |
| 4 June 2026 | Boor Kathryn Jean | Director | Grant or award | +16,875 | — | 25,138 | Form 4 |
| 12 March 2026 | Mayo Stephen | Director | Open-market sale | −7,239 | $17.02 | 1,765 | Form 4 |
| 11 March 2026 | Rothfuss Cristin | EVP, General Counsel | Shares withheld for tax | −974 | $17.03 | 137,544 | Form 4 |
| 11 March 2026 | Rodino-Klapac Louise | President, R&D and Tech Ops | Shares withheld for tax | −948 | $17.03 | 225,323 | Form 4 |
| 11 March 2026 | Wong Ryan Ho-Yan | Chief Financial Officer | Shares withheld for tax | −256 | $17.03 | 135,064 | Form 4 |
| 11 March 2026 | Estepan Ian Michael | Chief Operating Officer | Shares withheld for tax | −1,097 | $17.03 | 201,983 | Form 4 |
| 9 March 2026 | Estepan Ian Michael | Chief Operating Officer | Shares withheld for tax | −1,036 | $16.95 | 203,663 | Form 4 |
| 9 March 2026 | Estepan Ian Michael | Chief Operating Officer | Shares withheld for tax | −583 | $16.95 | 203,080 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Sarepta Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.